SMO was found to be elevated in both prostate adenocarcinoma and prostatic intraepithelial neoplasia [67] whereas breast cancer showed SMOX underexpression at both mRNA and protein levels [68]. This evidence concerns the gene SMOX and prostate adenocarcinoma.